Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUTREBIS vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DUTREBIS (fixed-dose combination of dapagliflozin and exenatide) combines a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist. Dapagliflozin inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. Exenatide activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Reducing risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease (dapagliflozin component),Reducing risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors (dapagliflozin component)
Hypertension
Dutasteride 0.5 mg orally once daily.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal half-life of 8–10 hours in healthy adults, extended to 12–15 hours in moderate renal impairment (Cr Cl 30–59 m L/min); requires dose adjustment in severe renal impairment.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Dapagliflozin is primarily metabolized via uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) to an inactive metabolite. Exenatide is degraded by proteolytic degradation and eliminated via glomerular filtration with subsequent tubular reabsorption and metabolic catabolism.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Approximately 70% renal (mostly as unchanged drug via glomerular filtration and active tubular secretion), 20% fecal (via biliary excretion), and 10% metabolized with metabolites excreted equally.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
99% bound to albumin and alpha-1-acid glycoprotein.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Vd 12–15 L/kg, indicating extensive extravascular distribution and high tissue binding (primarily to erythrocytes and vascular smooth muscle).
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: 45% (range 30–60%), due to incomplete absorption and first-pass metabolism. Food decreases rate but not extent.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
No dose adjustment required for renal impairment. Dutasteride is not significantly renally eliminated.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B); no specific dose adjustment guidelines available.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not indicated in pediatric patients (<18 years). No established dosing.
Not established; avoid use in children.
No specific dose adjustment required based on age alone. Monitor for adverse effects, particularly dizziness and hypotension, in elderly patients.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None
None
Pancreatitis: Acute pancreatitis has been reported; discontinue if suspected,Diabetic ketoacidosis: SGLT2 inhibitors can cause ketoacidosis even with normal blood glucose levels,Volume depletion: May cause intravascular volume contraction and hypotension,Acute kidney injury: Monitor renal function,Hypoglycemia: Increased risk when used with insulin or insulin secretagogues,Severe gastrointestinal disease: Exenatide is not recommended in patients with severe gastrointestinal disease,Immunogenicity: Antibody formation to exenatide may occur
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
History of hypersensitivity to dapagliflozin, exenatide, or any excipients,Severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease (dapagliflozin component),Personal or family history of medullary thyroid carcinoma (exenatide component, based on animal studies),Patients with multiple endocrine neoplasia syndrome type 2 (exenatide component)
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Take with food to reduce tamsulosin absorption variability and decrease dizziness risk. Avoid grapefruit juice as it may increase tamsulosin levels via CYP3A4 inhibition. No other specific dietary restrictions.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
DUTREBIS (dutasteride and tamsulosin) is contraindicated in pregnancy. Dutasteride is a potent inhibitor of 5α-reductase, which can inhibit the conversion of testosterone to dihydrotestosterone (DHT). In animal studies, dutasteride caused feminization of male fetuses and impaired reproductive development. The risk is highest during the first trimester when sexual differentiation occurs. Tamsulosin, an alpha-1 adrenergic antagonist, is associated with fetal hypotension and hypoxia. No human data exist; both drugs should be avoided in pregnancy.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
DUTREBIS is contraindicated in breastfeeding. Dutasteride is excreted in human milk in animal studies; tamsulosin is excreted in rat milk. M/P ratio is unknown. Both drugs may cause adverse effects in the nursing infant, including hypotension and hormonal disruption.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
DUTREBIS is contraindicated in pregnancy and should not be used. No dose adjustments are applicable. Decreased drug clearance in pregnancy may theoretically increase exposure, but no data are available.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
DUTREBIS (dutasteride and tamsulosin) is a fixed-dose combination for benign prostatic hyperplasia (BPH). Dutasteride is a 5-alpha-reductase inhibitor that reduces DHT levels, requiring 6 months for maximal effect. Tamsulosin is an alpha-1 blocker that provides rapid symptom relief within 2-4 weeks. Monitor for orthostatic hypotension, especially in elderly; titrate tamsulosin dose if needed. Check PSA levels before and during therapy; dutasteride reduces PSA by ~50%. Avoid in women, children, and patients with history of prostate cancer. Use with caution with strong CYP3A4 inhibitors (e.g., ketoconazole) due to increased tamsulosin exposure.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take the capsule 30 minutes after the same meal each day, preferably breakfast.,Do not crush, chew, or open the capsule; swallow whole.,Frequent ejaculation may reduce risk of retrograde ejaculation; inform if this occurs.,Rise slowly from lying or sitting to avoid dizziness or fainting.,Use effective contraception if partner is pregnant or may become pregnant; decomtamination in semen.,Report any breast lump, pain, or nipple discharge immediately.,Avoid driving until you know how the medication affects you; may cause dizziness.,Do not take with other alpha-blockers for prostate or blood pressure without doctor approval.,PSA levels will be reduced by half; inform your doctor of this effect.,Long-term treatment (6+ months) needed for maximal benefit on urinary symptoms.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUTREBIS vs ALDORIL 25, answered by our medical review team.
DUTREBIS is a Antihypertensive Combination that works by DUTREBIS (fixed-dose combination of dapagliflozin and exenatide) combines a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist. Dapagliflozin inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. Exenatide activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUTREBIS and ALDORIL 25 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUTREBIS is: Dutasteride 0.5 mg orally once daily.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUTREBIS and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUTREBIS is classified as Category C. DUTREBIS (dutasteride and tamsulosin) is contraindicated in pregnancy. Dutasteride is a potent inhibitor of 5α-reductase, which can inhibit the conversion of testosterone to dihydr. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.